GlassScriptPhysician profile
Dipa M Patel
NPI 1033857495
$3,100.66
in general payments reported to CMS, 2019-2025
29 companies · $1,100 in 2025
The $1,100 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $481 · 2023: $971 · 2024: $548 · 2025: $1,100.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,502 · Education: $117.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,502.36 |
| Education | $117.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $373.31 | 2022-2025 | Jardiance, Tradjenta, Synjardy |
| Lilly USA, LLC | $340.22 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $291.66 | 2022-2025 | Farxiga, Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $268.23 | 2023-2025 | |
| Amgen INC. | $224.71 | 2022-2025 | Otezla, Repatha, Otezla |
| Glaxosmithkline, LLC. | $188.12 | 2022-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Abbvie INC. | $181.96 | 2023-2025 | |
| Astellas Pharma US INC | $146.26 | 2023-2024 | Veozah |
| Pfizer INC. | $139.81 | 2022-2025 | |
| Novo Nordisk INC | $110.62 | 2023-2025 | Rybelsus, Ozempic |
| Biohaven Pharmaceutical Holding Company LTD. | $98.00 | 2022 | |
| Ibsa Pharma INC. | $94.27 | 2022-2025 | Licart, Tirosint, Flector |
| Lexicon Pharmaceuticals, INC. | $76.08 | 2024 | |
| Sumitomo Pharma America, INC. | $74.50 | 2023-2025 | Gemtesa |
| E.R. Squibb & Sons, L.L.C. | $64.16 | 2022-2023 | Eliquis |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $54.35 | 2023-2025 | Cologuard Collection Kit |
| Corcept Therapeutics | $43.64 | 2023 | Korlym |
| Axsome Therapeutics, INC. | $39.76 | 2025 | Symbravo |
| Phathom Pharmaceuticals, INC. | $38.15 | 2025 | Voquezna |
| Opko Pharmaceuticals, LLC | $37.36 | 2022-2023 | Rayaldee |
| Idorsia Pharmaceuticals US INC | $34.42 | 2023 | Quviviq |
| Amarin Pharma, INC. | $32.63 | 2022-2023 | |
| Otsuka America Pharmaceutical, INC. | $30.90 | 2023-2024 | Rexulti |
| Alexion Pharmaceuticals, INC. | $24.40 | 2023 | Ultomiris |
| Novartis Pharmaceuticals Corporation | $24.35 | 2025 | |
| Janssen Pharmaceuticals, INC | $22.12 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $17.53 | 2023 | Seglentis |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.77 | 2025 | Xifaxan |
| Lundbeck LLC | $14.37 | 2023 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dipa Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.